However, in all of the molecular subtypes, triple-negative breast cancer (TNBC) which is characterized by a loss of ER, PR and HER-2 is the most tough situation and the total number of the patients approximately accounts for 10–20% of all breast cancer patients that is not a small percentage that can be ignored (Boyle, 2012). This evidence concerns the gene ERBB2 and breast cancer.